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Glycogen metabolism operates as an alternative energy source, enabling cell growth under conditions
of metabolic stress. Favaro et al. (2012) now demonstrate that in hypoxic cancer cells, depletion of liver
glycogen phosphorylase causes glycogen accumulation, leading to oxidative stress, induction of senes-
cence, and impaired tumor growth in vivo.Among the various metabolic adaptations
employed by cancer cells to adjust to the
conditions imposed by the tumor micro-
environment, changes in glycogen meta-
bolism are emerging as an essential
response (Brahimi-Horn et al., 2011).
Understanding the role of glycogen
metabolism in neoplastic transformation
requires a better knowledge of how this
metabolic pathway is regulated in cancer.
Favaro et al. now demonstrate that inhibi-
tion of glycogen mobilization in cancer
cells leads to the induction of senes-
cence and impairs tumor growth (Favaro
et al., 2012).
Hypoxia is an important component of
the tumor microenvironment and regu-
lates several processes essential for
tumor formation. Hypoxia promotes the
storage of glucose in the form of glycogen
in nonmalignant as well as in cancer cells
for later use under more drastic, nutrient-
limiting conditions (Brahimi-Horn et al.,
2011). A previous study showed that
nonmalignant cells exposed to low
oxygen induce the expression of GYS1,
the muscle isoform of glycogen synthase
(the key enzyme involved in glycogen
synthesis), using a mechanism depen-
dent on the hypoxia-inducible factor
(HIF) (Pescador et al., 2010). However,
the activity of glycogen phosphorylase
(the key enzyme involved in glycogen
degradation) was decreased (Pescador
et al., 2010). Parallel findings were re-
ported in human MCF-7 breast cancer
cells (Shen et al., 2010). In this system,
short-term hypoxia led to glycogen accu-
mulation by the HIF-dependent induction
of protein phosphatase 1 regulatory
subunit 3C (PPP1R3C or PTG). This acti-
vated glycogen synthase and decreased
glycogen phosphorylase activity (Shen
et al., 2010). On the other hand, the liver
isoform of glycogen phosphorylase(PYGL) was previously found among the
99 genes included in a hypoxia ‘‘meta-
gene’’ signature, which predicts poor
survival in head and neck squamous cell
carcinomas and breast cancer (Winter
et al., 2007). Therefore, the role of
glycogen degradation in response to
hypoxia and in cancer cell survival re-
mained unclear.
To address this question, Favaro et al.
examined xenografts of U87 glioblastoma
cells in mice treated with the antiangio-
genic drug bevacizumab. They found
that hypoxic areas in the treated tumors
expressed both GYS1 and PYGL and
showed marked accumulation of gly-
cogen. Consistent with this finding, they
observed an acute induction of GYS1
expression and glycogen accumulation
in several cancer cell lines (U87 glioblas-
toma, MCF-7 breast cancer, and HCT-
116 colon cancer cells) exposed to
hypoxia. PYGL mRNA levels, on the other
hand, increased only after longer expo-
sure to hypoxia and correlated with
a reduction in glycogen content, suggest-
ing activation of glycogen breakdown
during the later stages of the hypoxia
response. Indeed, PYGL expression was
elevated in several different tumor types,
relative to normal tissues. Importantly,
silencing of PYGL, by siRNA, in different
cancer cell lines led to increased
glycogen content and resulted in induc-
tion of senescence, both in normoxia
and hypoxia, although the increase in
glycogen stores was more prominent in
low oxygen. Remarkably, PYGL silencing
by shRNA strongly impaired the growth
of the U87 xenograft cells.
To explain these findings, Favaro et al.
propose a model in which channeling of
glucose-6-phosphate toward the pentose
phosphate pathway (PPP), caused by
glycogen mobilization, is essential forCell Metabolism 16,the survival of cancer cells (Figure 1).
Based on this model, PYGL silencing
impairs glycogen breakdown, results in
decreased flux through the PPP, and
diminishes NADPH levels, which not only
provide the reductive power for the
synthesis of macromolecules for cell
growth and proliferation, but also main-
tain cellular redox balance. The increase
in reactive oxygen species (ROS) after
silencing of PYGL leads to p53 activation
and induction of senescence. In agree-
ment with this conclusion, Favaro et al.
found that induction of senescence was
partially reversed by cosilencing of p53
or treatment with a ROS scavenger.
However, it cannot be excluded that the
hyperaccumulation of glycogen itself has
an effect on cellular signaling processes
and contributes to the induction of senes-
cence. Evidence for this comes from the
cosilencing of glycogen synthase, which
resulted in diminished glycogen stores
and rescued the senescence phenotype.
Several published observations reinforce
this concept. The b1 subunit of AMPK
contains a glycogen-binding site, and
AMPK is believed to be in its active state
when glycogen particles are fully synthe-
sized. Persistent activation of AMPK can
lead to the induction of p53-dependent
cellular senescence (Jones et al., 2005).
Furthermore, sublethal doses of inhibitors
of glycogen synthase kinase 3 (GSK-3),
one of the kinases that regulates glycogen
synthesis through phosphorylation and
inhibition of glycogen synthase, have
also been reported to induce cellular
senescence accompanied by enhanced
glycogenesis and increased glycogen
content (Seo et al., 2008).
Previous studies suggested that short-
term hypoxia promotes accumulation of
glycogen by increasing glycogen syn-
thase activity while decreasing the activityDecember 5, 2012 ª2012 Elsevier Inc. 687
Figure 1. Overview of GlycogenMetabolism in Cancer Cells Exposed to Hypoxia and Effects
of PYGL Depletion
Favaro et al. report the induction of several enzymes involved in glycogen synthesis (blue) and degradation
(red) in cancer cells under hypoxic conditions. Channeling of glucose through glycogen promotes the
survival of cancer cells under hypoxia. Depletion of PYGL reduces glycogen mobilization and impairs
NADPH production due to decreased flux through the PPP, resulting in ROS accumulation and induction
of senescence. Branching enzyme 1, GBE1; glucose transporter 1, GLUT1; glycogen phosphorylase liver
isoform, PYGL; glycogen synthase muscle isoform, GYS1; glucose-1-phosphate, Glc-1-P; glucose-6-
phosphate, Glc-6-P; hexokinase II, HK-II; phosphoglucomutase 1, PGM-1; pentose phosphate pathway,
PPP; reactive oxygen species, ROS; UDP-glucose, UDP-Glc.
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Previewsof glycogen phosphorylase (Shen et al.,
2010). The results of Favaro et al. now
also implicate glycogen mobilization in
the late response of cancer cells to
hypoxia. The late induction of PYGL may
reflect the temporally dynamic nature of
glycogen metabolism within the hypoxia
response. This could be particularly
important in the context of fluctuating
nutrient and oxygen availability within
the tumor microenvironment.
These findings suggest that PYGL may
represent a target for anticancer therapy.
Drug discovery programs are already
exploring PYGL as a therapeutic target
for the treatment of type 2 diabetes, to re-
balance the defects in liver glycogen
metabolism that lead to the disturbance
of blood glucose homeostasis. It will be
of significant interest to investigate
whether the use of PYGL inhibitors, rather
than modulation of PYGL expression,
could be beneficial for the treatment of688 Cell Metabolism 16, December 5, 2012 ªcancer. However, it is important to
consider that the phosphorylated (active)
form of PYGL is a potent allosteric inhib-
itor of protein phosphatase-1 (PP1), which
dephosphorylates and activates glycogen
synthase (Agius, 2010). PYGL inhibition
could thus not only prevent glycogen
degradation but also promote its syn-
thesis, thereby further limiting the flux of
glucose-6-phosphate toward the PPP
(Figure 1). Indeed, other proteins involved
in glycogen metabolism, some of them
being regulated byHIF, have been already
proposed as therapeutic targets (Pelletier
et al., 2012; Pescador et al., 2010).
Regarding glycogen degradation, only
the G1 subunit of phosphorylase kinase
(PhKG1), the enzyme that phosphorylates
and thereby activates glycogen phos-
phorylase, has been described to be up-
regulated in human tumors (Camus
et al., 2012). With their important findings,
Favaro et al. now expand the repertoire of2012 Elsevier Inc.players involved in glycogen metabolism
that can be considered as targets for
future anticancer therapies.
The study by Favaro et al. highlights
glycogen metabolism as a promising
metabolic Achilles’ heel for cancer treat-
ment. Moreover, glycogen mobilization
could allow cancer cells to bypass limita-
tions in nutrient supply caused by antian-
giogenic drugs, making it an attractive
target for combination therapies. This
study paves the way for a better under-
standing of the regulation of this impor-
tant metabolic pathway in cancer.REFERENCES
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